Answer
Marstacimab (Hympavzi) should be used during pregnancy only if maternal benefit outweighs foetal risk, considering increased thrombosis risk during pregnancy and after childbirth and the association of several pregnancy complications with increased disseminated intravascular coagulation risk; foetal harm is unknown.
Sources for this answer
- Hympavzi 150 mg solution for injection in pre-filled penPfizer Limited · emc · SmPC §4.6 Fertility, pregnancy and lactation · Version 4Document updated
Sources checked